Your browser doesn't support javascript.
loading
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Herzog, Thomas J; Pignata, Sandro; Ghamande, Sharad A; Rubio, Maria-Jesús; Fujiwara, Keiichi; Vulsteke, Christof; Armstrong, Deborah K; Sehouli, Jalid; Coleman, Robert L; Gabra, Hani; Scambia, Giovanni; Monk, Bradley J; Arranz, José A; Ushijima, Kimio; Hanna, Rabbie; Zamagni, Claudio; Wenham, Robert M; González-Martín, Antionio; Slomovitz, Brian; Jia, Yan; Ramsay, Lisa; Tewari, Krishnansu S; Weil, Susan C; Vergote, Ignace B.
Afiliação
  • Herzog TJ; University of Cincinnati Cancer Center, Cincinnati, OH, USA. Electronic address: thomas.herzog@uc.edu.
  • Pignata S; Instituto Nazionale Tumori di Napoli IRCCS, Fondazione Pascale (MITO), Napoli, Italy.
  • Ghamande SA; Georgia Cancer Center, Augusta University, Augusta, GA, USA.
  • Rubio MJ; Hospital Universitario Reina Sofia, Grupo Español de Investigación en Cáncer de Ovario (GEICO) Group, Cordoba, Spain.
  • Fujiwara K; Saitama Medical University International Medical Center, Hidaka-City, Saitama, Japan.
  • Vulsteke C; Center for Oncological Research (CORE), Antwerp University and Integrated Cancer Center, Ghent, Belgium.
  • Armstrong DK; Johns Hopkins University, Baltimore, MD, USA.
  • Sehouli J; Charité-Universitätsmedizin Berlin and North-Eastern German Society for Gynecological Oncology (NOGGO), NOGGO, Germany.
  • Coleman RL; US Oncology Research, The Woodlands, TX, USA.
  • Gabra H; Imperial College, London, UK.
  • Scambia G; Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome, Rome, Italy.
  • Monk BJ; HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ, USA.
  • Arranz JA; HGU Gregorio Marañón, Madrid, Spain.
  • Ushijima K; Kurume University School of Medicine, Kurume, Japan.
  • Hanna R; Henry Ford Hospital, Detroit, MI, USA.
  • Zamagni C; IRCCS Azienda Ospedaliero universitaria di Bologna, Italy.
  • Wenham RM; Moffitt Cancer Center, Tampa, FL, USA.
  • González-Martín A; GEICO, Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain; Program in Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, Spain.
  • Slomovitz B; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
  • Jia Y; Eisai Inc., Exton, PA, USA.
  • Ramsay L; Eisai Inc., Exton, PA, USA.
  • Tewari KS; University of California, Irvine, Orange, CA, USA.
  • Weil SC; Eisai Inc., Exton, PA, USA.
  • Vergote IB; Belgium and Luxembourg Gynaecological Oncology Group (BGOG) and University Hospitals Leuven, Leuven, Belgium.
Gynecol Oncol ; 170: 300-308, 2023 03.
Article em En | MEDLINE | ID: mdl-36758420
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Epiteliais e Glandulares Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Female / Humans Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Epiteliais e Glandulares Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Female / Humans Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article